BeOne Medicines Ltd. (ONC) key performance indicators and operating metrics (41 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Global BRUKINSA revenue growth | 31.00 percent | FY2026-Q2 |
| U.S. BRUKINSA sales growth | 31.00 percent | FY2026-Q2 |
| BRUKINSA product revenue | 1.25B | FY2026-Q2 |
| TEVIMBRA product revenue | 228.52M | FY2026-Q2 |
| U.S. BRUKINSA sales | 893M | FY2026-Q2 |
| Total revenue growth | 30.00 percent | FY2026-Q2 |
| Product revenue growth | 29.00 percent | FY2026-Q2 |
| BRUKINSA approved markets | 80.00 | FY2026-Q2 |
| TEVIMBRA approved markets | 50.00 | FY2026-Q2 |
| Global TEVIMBRA sales growth | 18.00 percent | FY2026-Q2 |
| China revenue | 506.02M | FY2026-Q2 |
| Europe revenue | 208.76M | FY2026-Q2 |
| U.S. revenue | 766M | FY2026-Q1 |
| Rest-of-world sales | 76.09M | FY2026-Q2 |
Back to ONC overview · ONC earnings · ONC holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.